Tarsus Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Focus

Tarsus Pharmaceuticals (TARS) presented at the Goldman Sachs Healthcare Conference, highlighting the successful launch of Xtampi and its strategic growth initiatives. The company is investing $70-80 million in a DTC advertising campaign expected to impact sales in late 2025, while also expanding its sales force to target 15,000 eye care professionals. Tarsus is also pursuing expansion into ocular rosacea and Lyme disease markets, with a Phase 2 study for ocular rosacea planned for the latter half of 2025 and a potential Phase 2b study for Lyme disease in 2026, targeting a 20% refill rate for Xtampi and peak sales of over $1 billion.

Analysis

Tarsus Pharmaceuticals (NASDAQ:TARS) presented a strongly positive outlook at the Goldman Sachs 46th Annual Global Healthcare Conference, detailing the successful commercial trajectory of its flagship product, Xtampi, which has exhibited growing demand and revenues since its September 2023 launch. Key growth initiatives include an expanded sales force of 150 representatives targeting 15,000 high-prescribing eye care professionals (ECPs), and a substantial $70-80 million annual Direct-to-Consumer (DTC) advertising campaign, from which significant script uplift is anticipated in late 2025, particularly Q4. While Q2 2025 script guidance for Xtampi is set at 85,000 to 90,000, factoring in seasonal impacts, the company is focused on improving refill rates—currently reported in high single digits (8-9%) by third-party sources but potentially higher at 12-14% based on cohort analysis—towards a 20% target, crucial for its peak sales projection exceeding $1 billion. Beyond Xtampi, Tarsus is advancing its pipeline with a Phase 2 study for ocular rosacea commencing in H2 2025 (data H2 2026) and evaluating a Phase 2b study for a Lyme disease prophylactic for a potential 2026 start. International expansion is also underway, with an NDA submitted in China, European approval targeted by 2027 contingent on a preservative-free formulation, and regulatory discussions in Japan scheduled for later this year, all supported by a robust intellectual property portfolio extending into the late 2030s and early 2040s for key assets.

Key Decisions for Investors

• Investors should consider monitoring Xtampi script volumes and the return on investment from the $70-80 million Direct-to-Consumer campaign, particularly in late 2025, as key indicators of Xtampi's growth trajectory.
• The ability to achieve the targeted 20% refill rate for Xtampi is critical for realizing the projected peak sales of over $1 billion and should be closely watched.
• Progress in the pipeline, especially the Phase 2 ocular rosacea study results expected in H2 2026 and advancement of the Lyme disease program, offers significant long-term upside potential.
• International expansion efforts, including regulatory approvals in China and Europe (targeting 2027), represent key milestones for market diversification and revenue growth.
• Near-term performance should be viewed in light of current reliance on new prescriptions (NRx) and typical eye care market seasonality, with an expectation of increasing contribution from refills (TRx) over time.